For instance, targeted treatment of NSCLC patients with EGFR mutations could improve their survival time (Ghafoor et al., 2018; Hsu et al., 2019), and targeted therapy for anaplastic lymphoma kinase positive disease could also improve the prognosis of patients with metastatic NSCLC (McCoach et al., 2017). Here, ALK is linked to non-small cell lung carcinoma.